Evolution of Geographic Atrophy in Participants Treated with Ranibizumab for Neovascular Age-related Macular Degeneration.

ABSTRACT:

Purpose

To evaluate the risk factors, incidence, and rate of progression of geographic atrophy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ranibizumab.

Design

Post-hoc analysis of a prospective clinical study.

Participants

69 participants with nAMD in at least one eye.

Methods

Participants were prospectively treated in the study eye with 0.5 mg intravitreal ranibizumab. Study eyes received 4 monthly injections followed by pro re nata injections until a fluid-free macula was achieved on optical coherence tomography. Risk factors assessed included baseline demographics, treatment, and ocular characteristics on imaging. Eyes were evaluated on fundus autofluorescence (FAF) for GA. The rate of GA area growth in study and fellow

SUBMITTER: Thavikulwat AT 

PROVIDER: S-EPMC5473650 | biostudies-literature | 2017 Jan-Feb

REPOSITORIES: biostudies-literature